Création et validation d’une classification en grade de sévérité dans les maladies neuromusculaires : la classification NM-Score
Vuillerot C, Rippert P, Roche S, Bérard C, Margirier F, de Lattre C, Poirot I, Berruyer A, Tiffreau V, Fournier-Mehouas M, Bouhour F, Urtizberea JA, Renders A, Ecochard R; Le groupe d’étude NM-Score.
Ann Phys Rehabil Med. 2013. 56(9-10):673-86.
Development of a classification for neuromuscular disease patients in each of the three motor function domains (D1: standing and transfers; D2: axial and proximal function; D3: distal function). Several qualitative validation studies (according to the Delphi method) and quantitative validation studies (content validity, criterion validity and inter-rater reliability) were used. The inter-rater agreement was good when the classification was based on patient observation or an interview with the patient. Stronger correlations (according to Spearman’s coefficient) with the respective ‘‘gold standard’’ classifications were found for NM-Score D1 (0.86 vs. the Vignos Scale and [1]0.88 vs. MFM]-D1 and NM-Score D2 ([1]0.7 vs. the Brooke Scale and 0.64 vs. MFM-D2) than for NM-Score D3 (0.49 vs. the Brooke scale and [1]0.49 vs. MFM-D3). The NM-Score is a reliable, reproducible outcome measure with value in clinical practice and in clinical research for the description of patients and the constitution of uniform patient groups (in terms of motor function).
Keywords: Activities of daily living, Motor function, Neuromuscular disease, Outcome measure
Articles dans les revues scientifiques
Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: a French real-life observational study
Audic F, de la Banda MGG, Bernoux D, Ramirez-Garcia P, Durigneux J, Barnerias C, Isapof A, Cuisset JM, Cances C, Richelme C, Vuillerot C, Laugel V, Ropars J, Altuzarra C, Espil-Taris C, Walther-Louvier U, Sabouraud P, Chouchane M, Vanhulle C, Trommsdorff V, Pervillé...
Long-term benefit of enzyme replacement therapy with alglucosidase alfa in adults with Pompe disease: prospective analysis from the French Pompe Registry
Semplicini C, De Antonio M, Taouagh N, Béhin A, Bouhour F, Echaniz-Laguna A, Magot A, Nadaj-Pakleza A, Orlikowski D, Sacconi S, Salort-Campana E, Solé G, Tard C, Zagnoli F, Jean-Yves H, Hamroun D, Laforêt P; French Pompe Study Group J Inherit Metab Dis. 2020. doi:...
Muscle MRI: A biomarker of disease severity in Duchenne muscular dystrophy? A systematic review
Ropars J, Gravot F, Ben Salem D, Rousseau F, Brochard S, Pons C. Neurology. 2020. 94(3):117-133. Review to assess the evidence of a relationship between muscle MRI and disease severity in Duchenne muscular dystrophy (DMD). Correlations between motor function tests,...
Evaluation of Speed-Accuracy Trade-Off in a Computer Task to Identify Motor Difficulties in Individuals With Duchenne Muscular Dystrophy – A Cross-Sectional Study
da Silva TD, Ribeiro-Papa DC, Coe S, Malheiros SRP, Massetti T, Meira Junior CM, Nicolai Ré AH, Collett J, Monteiro CBM, Dawes H. Res Dev Disabil. 2020. 96:103541. The aim of the study was to evaluate movement time during a task at various levels of difficulty and to...
Timed immersion expiration measures in patients with muscular dystrophies
Voos MC, Goya PSA, de Freitas BL, Pires AMT, Favero FM, Caromano FA. Arch Physiother. 2020 18;10:4. doi: 10.1186/s40945-020-0074-3. eCollection 2020. The aim of the study was to describe the evolution of timed immersion expiration in 57 patients with muscular...
The Use of the Gait Profile Score and Gait Variable Score in Individuals With Duchenne Muscular Dystrophy
de Souza MA, Cezarani A, Lizzi EAD, Davoli GBQ, Mattiello SM, Jones R, Mattiello-Sverzut AC J Biomech. 2020. 98, 109485. Study of the applicability of the Gait Deviation Index (GDI) and the Gait Profile Score (GPS) in patients with duchenne Muscular Dystrophy, using...